Stock Analiz

MeiraGTx Holdings plc MGTX

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026

$9.18Market cap $897M
Open the interactive analysis →

MeiraGTx Holdings plc (MGTX) is a healthcare company listed in the US with a market value of about $897M. In the twelve months to September 30, 2026 it had revenue of $402M and net income of $78M, a net margin of 19.5%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 10.6, 5-year revenue growth of 39% a year, a 5-year average ROIC of -75%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.

About MeiraGTx Holdings

MeiraGTx Holdings is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $13M in 2019 to $81M in 2025, growth of about 35.3% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 78% over three years (dilution for shareholders). It spends 159% of revenue on research and development.

Score: 1.8 / 5

Value2/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Positive free cash flow

Valuation

P/E (TTM)10.6
Forward P/E—
P/FCF—
P/S2.2
P/B4.2
EV/EBITDA4.4
PEG—
Dividend yield0.00%
FCF yield-0.3%
Shareholder yield0.0%
Intrinsic value vs. price−60%

Growth and quality

Revenue growth (1 yr)144.6%
Revenue growth (5 yrs, per year)39.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-441.8%
ROIC (5-yr avg.)-74.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$402M$81M$33M$14M$16M$38M$16M$13M——
Net income$78M-$114M-$148M-$84M-$130M-$80M-$58M-$55M-$83M-$31M
Free cash flow-$3M-$50M-$109M-$126M-$118M-$57M-$85M$11M-$70M-$29M
EPS (diluted)$0.87$-1.42$-2.12$-1.49$-2.87$-1.80$-1.54$-1.65$-4.47$-3.72
Net margin19.5%-140.3%-444.1%-599.5%-814.2%-211.0%-372.6%-411.9%——
ROIC—-128.1%-107.6%-60.3%-43.8%-34.6%-24.0%-27.2%-95.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $27.75, 202% above the current price; targets range from $16.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $0.19 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is MeiraGTx Holdings’s P/E ratio?

About 10.6, based on the last twelve months of diluted earnings per share.

Is MeiraGTx Holdings stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does MeiraGTx Holdings pay a dividend?

Not currently.

Is MeiraGTx Holdings a good stock to buy?

We do not give buy or sell advice. MeiraGTx Holdings scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.